Effect of teriparatide versus alendronate or no medication on periprosethtic BMD in THA .
Teriparatide versus alendronate for the preservation of bone mineral density after total hip arthroplasty - a randomized controlled trial
J Arthroplasty. 2016 Jan;31(1):333-848 patients scheduled for cementless total hip arthroplasty (THA) were randomized to be postoperatively administered either daily subcutaneous teriparatide, weekly oral alendronate, or no medication. The purpose of this study was to measure and compare periprosthetic bone mineral density, defined by Gruen Zones, between groups over 48 week follow-up. In addition, serum levels of procollagen type-1 N-terminal propeptide (P1NP) and N-terminal telopeptides of type-1 collagen (NTx) were measured and assessed during follow-up. The largest decrease in BMD in all three groups was observed in Gruen Zone 7, and the degree of this decrease was significantly smaller in both the teriparatide group and alendronate group compared to the no medication group, though the difference between the teriparatide and alendronate groups was not statistically significant.
Unlock the Full ACE Report
You have access to 4 more FREE articles this month.
Click below to unlock and view this ACE Reports
Unlock Now
Critical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics
Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics
Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions
Exclusive access to original content articles, including in-house systematic reviews, and articles on health research methods and hot orthopaedic topics